CY1107620T1 - Πολυ-συστατικο εμβολιο για την προστασια εναντι της παθησης που προκαλειται απο haemophilus influenzae and moraxella catarrhalis - Google Patents

Πολυ-συστατικο εμβολιο για την προστασια εναντι της παθησης που προκαλειται απο haemophilus influenzae and moraxella catarrhalis

Info

Publication number
CY1107620T1
CY1107620T1 CY20071100548T CY071100548T CY1107620T1 CY 1107620 T1 CY1107620 T1 CY 1107620T1 CY 20071100548 T CY20071100548 T CY 20071100548T CY 071100548 T CY071100548 T CY 071100548T CY 1107620 T1 CY1107620 T1 CY 1107620T1
Authority
CY
Cyprus
Prior art keywords
moraxella catarrhalis
haemophilus influenzae
component
antigens
protection against
Prior art date
Application number
CY20071100548T
Other languages
English (en)
Inventor
Sheena M Loosmore
Yan-Ping Yang
Michel H Klein
Ken Sasaki
Original Assignee
Sanofi Pasteur Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23389874&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1107620(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Pasteur Limited filed Critical Sanofi Pasteur Limited
Publication of CY1107620T1 publication Critical patent/CY1107620T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Μία πολυ-σθενής ανοσογόνος σύνθεση που αποφέρει προστασία σε έναν ανοσοποιημένο ξενιστή έναντι της λοίμωξης που προκαλείται από αμφότερα τον Haemophilus influenzae και την Moraxella catarrhalis. Η σύνθεση αυτού του είδους περιλαμβάνει τέσσερα τουλάχιστον αντιγόνα περιλαμβάνοντας ένα τουλάχιστον αντιγόνο από τον Haemophilus influenzae, και ένα τουλάχιστον αντιγόνο από την Moraxella catarrhalis. Τρία από τα αντιγόνα είναι προσκολλητίνες. Οι πρωτεΐνες υψηλού μοριακού βάρους (HMW) και οι πρωτεΐνες προσκολλητίνης του Haemophilus influenzae (Hia) του μη-τυποποιήσιμου Haemophilus και μία πρωτεΐνη εξωτερικής μεμβράνης των 200 kDa της Moraxella catarrhalis περιλαμβάνουν τα συστατικά προσκολλητίνης, ενώ το άλλο αντιγόνο είναι ένα μη-πρωτεολυτικό ανάλογο της πρωτεΐνης Hin47. Το κάθε ένα συστατικό δεν μειώνει την ανοσογονικότητα των άλλων. Η πολυ-ασθενής ανοσογόνος σύνθεση μπορεί να συνδυαστεί με εμβόλια συστατικού DTP, η οποία μπορεί επίσης να συμπεριλαμβάνει μη-μολυσματικό πολυοϊό και PRP-T για την παροχή ενός συστατικού εμβολίου χωρίς εξασθένιση των ανοσογόνων ιδιοτήτων των άλλων αντιγόνων.
CY20071100548T 1999-07-15 2007-04-23 Πολυ-συστατικο εμβολιο για την προστασια εναντι της παθησης που προκαλειται απο haemophilus influenzae and moraxella catarrhalis CY1107620T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/353,617 US6391313B1 (en) 1999-07-15 1999-07-15 Multi-component vaccine to protect against disease caused by Haemophilus influenzae and Moraxella catarrhalis
EP00945494A EP1200122B1 (en) 1999-07-15 2000-07-11 Multi-component vaccine to protect against disease caused by haemophilus influenzae and moraxella catarrhalis

Publications (1)

Publication Number Publication Date
CY1107620T1 true CY1107620T1 (el) 2013-03-13

Family

ID=23389874

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100548T CY1107620T1 (el) 1999-07-15 2007-04-23 Πολυ-συστατικο εμβολιο για την προστασια εναντι της παθησης που προκαλειται απο haemophilus influenzae and moraxella catarrhalis

Country Status (12)

Country Link
US (1) US6391313B1 (el)
EP (2) EP1200122B1 (el)
AT (1) ATE353223T1 (el)
AU (1) AU767096B2 (el)
CA (1) CA2378862C (el)
CY (1) CY1107620T1 (el)
DE (1) DE60033291T2 (el)
DK (1) DK1200122T3 (el)
ES (1) ES2280230T3 (el)
PT (1) PT1200122E (el)
SI (1) SI1200122T1 (el)
WO (1) WO2001005424A2 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440425B1 (en) * 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
EP1203082A1 (en) * 1999-07-27 2002-05-08 Aventis Pasteur Limited Recombinant high molecular weight major outer membrane protein of moraxella
SE0102410D0 (sv) 2001-07-04 2001-07-04 Arne Forsgren Novel surface exposed immunoglobulin D-binding protein from moraxella catarrhalis
WO2009062112A2 (en) 2007-11-09 2009-05-14 The Salk Institute For Biological Studies Use of tam receptor inhibitors as antimicrobials
CN105175549B (zh) * 2015-09-30 2019-08-16 康希诺生物股份公司 一种流感嗜血杆菌融合蛋白及其构建方法与应用
WO2018178265A1 (en) * 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
CN110662557A (zh) * 2017-03-31 2020-01-07 葛兰素史克知识产权开发有限公司 免疫原性组合物、用途和治疗方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4496538A (en) 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
ES2063965T3 (es) * 1989-03-09 1995-01-16 Praxis Biolog Inc Vacunas para haemophilus influenzae no tipificable.
US5843463A (en) 1990-12-21 1998-12-01 Antexbiologics, Inc. Adhesin-oligosaccharide conjugate vaccine for Haemophilus influenzae
US5603938A (en) 1992-03-16 1997-02-18 St. Louis University High molecular weight surface proteins of non-typeable haemophilus
JPH11501003A (ja) * 1993-03-16 1999-01-26 セントルイス ユニヴァーシティ ノンタイプアブルヘモフィルスの高分子量表面タンパク
US5977336A (en) 1993-03-16 1999-11-02 St. Louis University High molecular weight surface proteins of non-typeable haemophilus
US5712118A (en) * 1993-09-29 1998-01-27 Research Foundation Of State University Of New York Vaccine for branhamella catarrhalis
US5506139A (en) 1994-07-21 1996-04-09 Connaught Laboratories Limited Analog of haemophilus Hin47 with reduced protease activity
US6764682B1 (en) 1994-06-16 2004-07-20 Aventis Pasteur Limited Adjuvant compositions containing more than one adjuvant
NZ291750A (en) 1994-07-21 1997-10-24 Connaught Lab Analogues of haemophilus influenzae hin47 protein with reduced protease activity
US5646259A (en) 1995-03-24 1997-07-08 St. Louis University DNA encoding haemophilus adhesion proteins
US6335018B1 (en) 1995-05-01 2002-01-01 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
IL136903A0 (en) * 1998-01-13 2001-06-14 Us Health Lipooligosaccharide-based vaccine for prevention of moraxella (branhamella) catarrhalis infections in mammals
US6974581B1 (en) * 1998-12-15 2005-12-13 Aventis Pasteur Limited Multi-component vaccine comprising at least two antigens from haemophilus influenzae to protect against disease

Also Published As

Publication number Publication date
EP1200122A2 (en) 2002-05-02
AU767096B2 (en) 2003-10-30
AU5958600A (en) 2001-02-05
DE60033291D1 (de) 2007-03-22
DE60033291T2 (de) 2007-07-05
SI1200122T1 (sl) 2007-08-31
DK1200122T3 (da) 2007-06-04
ATE353223T1 (de) 2007-02-15
ES2280230T3 (es) 2007-09-16
PT1200122E (pt) 2007-05-31
CA2378862A1 (en) 2001-01-25
CA2378862C (en) 2005-05-10
US6391313B1 (en) 2002-05-21
WO2001005424A3 (en) 2001-08-02
EP1880734A3 (en) 2008-06-25
WO2001005424A2 (en) 2001-01-25
EP1200122B1 (en) 2007-02-07
EP1880734A2 (en) 2008-01-23

Similar Documents

Publication Publication Date Title
CY1107620T1 (el) Πολυ-συστατικο εμβολιο για την προστασια εναντι της παθησης που προκαλειται απο haemophilus influenzae and moraxella catarrhalis
CY1110359T1 (el) Εμβολια με βαση σιρκοϊους χοιρων
WO2008026225A3 (en) A vaccine for chikungunya virus infection
CY1114333T1 (el) Αντιγονα του neisseria meningitidis
CY1115842T1 (el) Συμπληρωμενο ομv εμβολιο κατα μηνιγγιtiδοκοκκου
NO20075902L (no) Forbindelser for immunoterapi og diagnose av turberkolose og metoder for deres anvendelse
NO20050396L (no) Adjuvant viral partikkel
CY1105010T1 (el) Πεπτιδια που λαμβανονται απο τη συνδεση (g) πρωτεϊνης του αναπνευστικου συνκυτιακου ιου
WO1998046725A3 (en) Attenuated, invasive vaccines against fish pathogens
CY1106252T1 (el) Εμβολιο πολλαπλων συστατικων που πepιλαμβανει τουλαχιστον δυο αντιγονα απο haemophilus influenzae για την προστασια εναντι νοσησης
ATE310014T1 (de) Hepatitis b-impfstoff
DE3689622D1 (de) Impfstoffe gegen menschliche respiratorische viren.
BR9704879A (pt) Composição de vacina e uso de um vírus cav vivo
DE68915046D1 (de) Haemophilus influenzae Typ B Polysaccharid-Aussermembranprotein-Konjugat als Impfstoff.
HUP9904171A2 (hu) A ragadós száj- és körömfájás vírusok immunogén peptidjei
WO2002009749A3 (en) Respiratory syncytial virus vaccine
DE69922212D1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
BR9709993A (pt) Vacina preparação de vacina composição processo para produção de uma preparação imugênica e preparação imugênica
CA2366316A1 (en) Multi-component vaccine comprising at least three antigens to protect against disease caused by haemophilus influenzae
AU6435596A (en) Pasteurella haemolytica type A-1 bacterin-toxoid vaccine
FR2724385B1 (fr) Vaccin de la peritonite infectieuse feline.
DE69228063D1 (de) Abgeschwächter rückmutierter virusimpfstoff gegen mareks krankheit serotyp-1